TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05450978

Intervention type: DRUG
Intervention: Lamotrigine
Description: Anti-seizure concentrations

Intervention type: DRUG
Intervention: Levetiracetam
Description: Anti-seizure concentrations
Study: NCT05468918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo previous generation hearing aids
Description: Receiver-in-canal (RIC) hearing aids with universal earpieces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo previous generation hearing aids
Description: Receiver-in-canal (RIC) hearing aids with universal earpieces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo Lumity hearing aids
Description: Receiver-in-canal (RIC) hearing aids with universal earpieces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo Lumity hearing aids
Description: Receiver-in-canal (RIC) hearing aids with universal earpieces
Study: NCT06006286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Given by Injection (inj)
Study: NCT04753567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nCap pain relief patch
Description: Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Patch
Description: Sham patch will be worn for 3 weeks exactly like actual pain patch
Study: NCT04743232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision tool for clinicians
Description: Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
Study: NCT06024226

Intervention type: PROCEDURE
Intervention: Tumor samples
Description: Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
Study: NCT05507528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reborn treatment
Description: Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
Study: NCT05381597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination cream of 5-fluorouracil and calcipotriene
Description: Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil cream
Description: Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
Study: NCT05954819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Planned patient education
Description: Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
Study: NCT04337450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) and lamivudine (3TC)
Description: Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: 2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
Study: NCT05609747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
Study: NCT05146232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: induction of anesthesia
Description: induction of anesthesia during gastric sleeve surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: induction of anesthesia
Description: induction of anesthesia during gastric sleeve surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maintainance of anesthesia
Description: maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maintainance of anesthesia
Description: maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
Study: NCT06437028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-layer perinatal tissue allograft
Description: The dual-layer perinatal tissue allograft is an amnion - amnion allograft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-layer fenestrated perinatal tissue allograft
Description: The three-layer fenestrated perinatal tissue allograft is an amnion - chorion - amnion allograft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
Study: NCT06184594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eNav
Description: The eNav toolkit is a digital navigation toolkit that includes a website and text messaging support. The website includes information, motivational support, decisional support and cues to action (e.g., ability to request a CRC screening test). The eNav tool also includes text-messaging based navigation (e.g., reminders, instructions to complete the screening test).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care procedures for selecting their CRC screening test.
Study: NCT05518032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Dendritic Cells
Description: Given intratumorally
Study: NCT05633082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 1 (omafilcon B)
Description: Toric daily wear contact lens for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens 2 (fanfilcon A)
Description: Toric daily wear contact lens for 15 minutes
Study: NCT06294587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FGG Before GBR
Description: Free Gingival Graft before the guided bone regeneration,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FGG after GBR
Description: Free Gingival Graft after the guided bone regeneration,
Study: NCT06456671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All nicotine/ tobacco products at market price
Description: Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All nicotine/ tobacco products at market price
Description: Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping products at 1/2 market price
Description: Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine vaping products at 1/2 market price
Description: Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated tobacco products at 1/2 market price.
Description: Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heated tobacco products at 1/2 market price.
Description: Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine pouch products at 1/2 market price.
Description: Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine pouch products at 1/2 market price.
Description: Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
Study: NCT06564571

Intervention type: DEVICE
Intervention: Patients undergoing endoscopic ultrasound procedures
Description: Patients will undergo endoscopic ultrasound procedures as planned. Abnormalities in the pancreas identified by the endoscopist during the endoscopic ultrasound examination will be correlated against those detected by the AI platform.
Study: NCT05029388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
Study: NCT06519526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-0302
Description: SHR-0302 will be administered orally as tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2554
Description: SHR-2554 will be administered orally as tablets.
Study: NCT04956016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic rTMS using the 8-shaped coil
Description: 20 rTMS sessions are planned (5 sessions per week)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep rTMS using the H1-shaped coil
Description: 20 rTMS sessions are planned (5 sessions per week)
Study: NCT04794504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 100 UNT Injection
Description: Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Injection
Description: As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
Study: NCT06003504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First aid training with blended learning approach
Description: The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First aid training with face-to-face approach
Description: The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross.
Study: NCT05918185

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Undergo cGA

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study: NCT05022719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam Colon2 procedure with MB-MMX
Description: Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
Study: NCT04907084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serine
Description: Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serine
Description: Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serine
Description: Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Serine
Description: Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 160mg pill, taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 160mg pill, taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 160mg pill, taken orally
Study: NCT04539405

Intervention type: DEVICE
Intervention: To evaluate sevoflurane consumption when using Memsorb
Description: Sevoflurane administration at 0.2L.min-1 (minimal gas flow)

Intervention type: DEVICE
Intervention: To evaluate sevoflurane consumption when using classical Dräegersorb
Description: Sevoflurane administration at 2L.min-1 (classical gas flow)
Study: NCT06571526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External focus
Description: The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
Study: NCT05021263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Medications
Description: IV magnesium sulfate, used to replete magnesium stores

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT05681663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroshock Wave therapy
Description: Randomized- Controlled trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroshock Wave therapy
Description: Randomized- Controlled trial
Study: NCT04471142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular bandage
Description: After the dressing is performed by the nursing team with a sterile gauze covering over the region of the healing points, the 7 cm wide Vitaltape® neuromuscular bandage will be applied. For the application of the bandage, maximum stretching will be performed over the region of the plastron and finished with the two ends, from two to three centimeters, without stretching. As many bundles of bandages as necessary will be applied according to the patient's body characteristics.
Study: NCT06571526

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
Study: NCT06409013

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06283966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/9.6 μg
Description: Glycopyrronium and formoterol fumarate pressurized inhalation suspension
Study: NCT05771012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin (Restasis®, Allergan Inc)
Description: study the efficacy of topical 0.05% cyclosporin eye drops (Restasis®, Allergan Inc) in management of grade 1 and 2 acquired punctal stenosis (group A)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mini-monoka stent
Description: insertion of mini-monoka stent in the lower punctum in management of grade 1 and 2 acqquired punctal stenosis (group B)
Study: NCT05821400

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT05788120

Intervention type: OTHER
Intervention: Follow up by phone call
Description: Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
Study: NCT06059573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant robot
Description: Implant placement will be navigated by a dental implant robot based on a digital plan.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand surgery
Description: Implant will be placed under freehand surgery.